STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Natera, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filing for Natera, Inc. (NTRA) reporting a proposed sale of 14,083 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $2,253,232.54. The shares represent restricted stock acquired from the issuer on 09/28/2025 and the filer indicates the approximate date of sale as 10/01/2025 on NASDAQ. The filing lists five prior sales by the same person during the past three months totaling 23,943 shares with gross proceeds shown for each sale. The notice includes the standard attestation that the seller does not possess undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider proposes to sell 14,083 restricted shares valued at $2.25M, previously acquired from the issuer on 09/28/2025.

The filing documents a Rule 144 notice for sale of restricted stock via Morgan Stanley Smith Barney LLC with a listed approximate sale date of 10/01/2025. The seller previously executed multiple transactions in the last three months; the schedule provides amounts and gross proceeds for five prior sales. This is a routine insider liquidity filing and contains the standard attestation regarding material nonpublic information.

TL;DR: Routine compliance disclosure: insider selling restricted shares under Rule 144 using a broker.

The form shows acquisition type as "Restricted Stock" from the issuer and lists acquisition and payment dates as 09/28/2025. The form includes the standard signature attestation language required by Rule 144 filings. No additional contractual details, plan-adoption dates, or indications of reliance on a 10b5-1 trading plan are provided in the filing.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for NTRA report?

The Form 144 reports a proposed sale of 14,083 restricted shares of Natera common stock with an aggregate market value of $2,253,232.54 via Morgan Stanley Smith Barney LLC.

When were the shares acquired and when is the approximate sale date?

The shares were acquired on 09/28/2025 (listed as restricted stock) and the approximate date of sale is 10/01/2025.

How many shares has the person sold in the past three months?

The filing lists five prior sales totaling 23,943 shares sold on dates between 07/01/2025 and 09/02/2025, with gross proceeds shown for each sale.

Which broker will execute the proposed sale?

The broker named in the filing is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Does the filing state the seller has undisclosed material information?

The filer includes the required attestation that they do not know any undisclosed material adverse information regarding the issuer.
Natera Inc

NASDAQ:NTRA

NTRA Rankings

NTRA Latest News

NTRA Latest SEC Filings

NTRA Stock Data

32.73B
133.33M
3.2%
96.35%
2.7%
Diagnostics & Research
Services-medical Laboratories
Link
United States
AUSTIN